Andrew East
Head of IDU Device Development & Manufacturing Biogen
Andrew East, based in Avon, MA, US, is currently a Head of IDU Device Development and Manufacturing at Biogen. Andrew East brings experience from previous roles at Alcyone Therapeutics Inc. and Alcyone Lifesciences / Anuncia Inc.. Andrew East holds a 1996 – 2001 University of Vermont. With a robust skill set that includes FDA, ISO 13485, Manufacturing, Six Sigma, Medical Devices and more. Andrew East has 3 emails and 1 mobile phone numbers on RocketReach.
Seminars
Thursday 3rd December 2026
Panel Discussion: Direct vs Systemic Delivery: Driving Pharma Buy-In, Bottlenecks & Patient Perception
2:30 pm
- Compare direct CNS delivery and systemic administration in terms of tissue exposure and selectivity, and their impact on target-site concentration, dose, and efficacy–toxicity balance
- Assess the limitations of systemic approaches that rely on plasma pharmacokinetics as a surrogate for efficacy versus direct delivery strategies that prioritise disease-site exposure
- Evaluate adoption barriers and translational challenges for direct delivery relative to systemic modalities, including device integration and demonstration of tissue-level pharmacological advantage
- Explore how patient, clinician, and commercial perspectives shape trade-offs between invasiveness and the potential for improved efficacy and reduced toxicity through targeted delivery
Thursday 3rd December 2026
Advancing Chronic Intrathecal Delivery via Implantable Port-Catheter Systems to Improve CNS Therapeutic Access & Patient Experience
11:30 am
- Introducing the design and functionality of implantable intrathecal port‑catheter systems enabling repeat access to cerebrospinal fluid for CNS therapeutic delivery
- Evaluating how device-enabled delivery can reduce reliance on repeated lumbar punctures and improve patient experience adherence and long-term feasibility
- Sharing clinical progress and learnings from ongoing studies assessing safety performance and real-world usability of implantable intrathecal delivery platforms
- Exploring the future role of integrated drug-device solutions in scaling antisense oligonucleotide and advanced therapy delivery across CNS indications
